Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Interstitial high-dose-rate brachytherapy in the primary treatment of inoperable glioblastoma multiforme.

Chatzikonstantinou G, Ulrich P, Archavlis E, Zamboglou N, Strouthos I, Zoga E, Baltas D, Tselis N.

J Contemp Brachytherapy. 2019 Jun;11(3):215-220. doi: 10.5114/jcb.2019.85722. Epub 2019 Jun 28.

2.

CT-guided interstitial HDR-brachytherapy for recurrent glioblastoma multiforme: a 20-year single-institute experience.

Chatzikonstantinou G, Zamboglou N, Archavlis E, Strouthos I, Zoga E, Milickovic N, Hilaris B, Baltas D, Rödel C, Tselis N.

Strahlenther Onkol. 2018 Dec;194(12):1171-1179. doi: 10.1007/s00066-018-1358-3. Epub 2018 Sep 10.

PMID:
30203110
3.

Computed tomography-guided interstitial high dose rate brachytherapy for centrally located liver tumours: a single institution study.

Tselis N, Chatzikonstantinou G, Kolotas C, Milickovic N, Baltas D, Zamboglou N.

Eur Radiol. 2013 Aug;23(8):2264-70. doi: 10.1007/s00330-013-2816-z. Epub 2013 Mar 21.

PMID:
23515917
4.

CT-guided interstitial HDR brachytherapy for recurrent glioblastoma multiforme. Long-term results.

Tselis N, Kolotas C, Birn G, Röddiger S, Filipowicz I, Kontova M, Fountzilas G, Selviaridis P, Baltas D, Heyd R, Anagnostopoulos G, Zamboglou N.

Strahlenther Onkol. 2007 Oct;183(10):563-70.

PMID:
17896088
5.

Computed tomography-guided interstitial high-dose-rate brachytherapy in the local treatment of primary and secondary intrathoracic malignancies.

Tselis N, Ferentinos K, Kolotas C, Schirren J, Baltas D, Antonakakis A, Ackermann H, Zamboglou N.

J Thorac Oncol. 2011 Mar;6(3):545-52. doi: 10.1097/JTO.0b013e318208c7a3.

6.

Adjuvant high-dose-rate brachytherapy after external beam radiotherapy in nasopharyngeal carcinoma.

Ozyar E, Yildz F, Akyol FH, Atahan IL.

Int J Radiat Oncol Biol Phys. 2002 Jan 1;52(1):101-8.

PMID:
11777627
7.

Survival analysis of HDR brachytherapy versus reoperation versus temozolomide alone: a retrospective cohort analysis of recurrent glioblastoma multiforme.

Archavlis E, Tselis N, Birn G, Ulrich P, Baltas D, Zamboglou N.

BMJ Open. 2013 Mar 15;3(3). pii: e002262. doi: 10.1136/bmjopen-2012-002262.

8.
9.

Hypofractionated accelerated computed tomography-guided interstitial high-dose-rate brachytherapy for liver malignancies.

Tselis N, Chatzikonstantinou G, Kolotas C, Milickovic N, Baltas D, Chung TL, Zamboglou N.

Brachytherapy. 2012 Nov-Dec;11(6):507-14. doi: 10.1016/j.brachy.2012.02.006. Epub 2012 May 8.

PMID:
22571828
10.

Radiation dose escalation for localized prostate cancer: intensity-modulated radiotherapy versus permanent transperineal brachytherapy.

Wong WW, Vora SA, Schild SE, Ezzell GA, Andrews PE, Ferrigni RG, Swanson SK.

Cancer. 2009 Dec 1;115(23):5596-606. doi: 10.1002/cncr.24558.

11.

High-dose-rate interstitial brachytherapy in head and neck cancer: do we need a look back into a forgotten art - a single institute experience.

Bhalavat R, Chandra M, Pareek V, Nellore L, George K, Nandakumar P, Bauskar P.

J Contemp Brachytherapy. 2017 Apr;9(2):124-131. doi: 10.5114/jcb.2017.67147. Epub 2017 Apr 13.

12.

Interim report of image-guided conformal high-dose-rate brachytherapy for patients with unfavorable prostate cancer: the William Beaumont phase II dose-escalating trial.

Martinez AA, Kestin LL, Stromberg JS, Gonzalez JA, Wallace M, Gustafson GS, Edmundson GK, Spencer W, Vicini FA.

Int J Radiat Oncol Biol Phys. 2000 May 1;47(2):343-52.

PMID:
10802358
14.

Combined high dose rate brachytherapy and external beam radiotherapy for clinically localised prostate cancer.

Strouthos I, Chatzikonstantinou G, Zamboglou N, Milickovic N, Papaioannou S, Bon D, Zamboglou C, Rödel C, Baltas D, Tselis N.

Radiother Oncol. 2018 Aug;128(2):301-307. doi: 10.1016/j.radonc.2018.04.031. Epub 2018 May 12.

PMID:
29764692
15.

Long-term results of chemoradiation plus pulsed-dose-rate brachytherapy boost in anal canal carcinoma: A mono-institutional retrospective analysis.

Arcelli A, Buwenge M, Macchia G, Cammelli S, Deodato F, Cilla S, Galuppi A, Panni V, Mattiucci GC, Tagliaferri L, Morganti AG.

J Contemp Brachytherapy. 2019 Feb;11(1):21-27. doi: 10.5114/jcb.2019.82804. Epub 2019 Feb 28.

16.

Interstitial brachytherapy for stage I and II squamous cell carcinoma of the oral tongue: factors influencing local control and soft tissue complications.

Fujita M, Hirokawa Y, Kashiwado K, Akagi Y, Kashimoto K, Kiriu H, Matsuura K, Ito K.

Int J Radiat Oncol Biol Phys. 1999 Jul 1;44(4):767-75.

PMID:
10386633
17.

High-dose-rate interstitial brachytherapy in recurrent head and neck cancer: an effective salvage option.

Bhalavat R, Pareek V, Chandra M, Nellore L, George K, Borade D, Kalariya K, Moosa Z, Srivastava A, Reddy N, Kapoor A, Kawale D, P N, Bauskar P.

J Contemp Brachytherapy. 2018 Oct;10(5):425-430. doi: 10.5114/jcb.2018.78995. Epub 2018 Oct 15.

18.

Interstitial brachytherapy for childhood soft tissue sarcoma.

Laskar S, Bahl G, Ann Muckaden M, Puri A, Agarwal MG, Patil N, Shrivastava SK, Dinshaw KA.

Pediatr Blood Cancer. 2007 Oct 15;49(5):649-55.

PMID:
17226842
20.

Perioperative interstitial brachytherapy for soft tissue sarcomas: prognostic factors and long-term results of 155 patients.

Laskar S, Bahl G, Puri A, Agarwal MG, Muckaden M, Patil N, Jambhekar N, Gupta S, Deshpande DD, Shrivastava SK, Dinshaw KA.

Ann Surg Oncol. 2007 Feb;14(2):560-7. Epub 2006 Nov 11.

PMID:
17115103

Supplemental Content

Support Center